Share:
ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) Pharvaris (NASDAQ:PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the presentation of clinical data supporting the multiple-dose safety and pharmacokinetic (PK) profile of PHA121 (PHA-022121) for the treatment of hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, being held virtually from July 10-16, 2021.
The double-blind, randomized, placebo-controlled, multiple ascending dose study included 38 male and female healthy volunteers. PHA121 was orally administered after standardized meals twice daily (BID) for 10 days in four sequential dosing cohorts, ranging from 12 to 50 mg, with safety and PK assessments during treatment and follow-up for 72 hours after the
Switzerland
United-states
Peng-lu
Berndt-modig
Maggie-beller
Sarah-mccabe
Exchange-commission
Stern-investor-relations-inc
European-union
Russo-partners
European-academy-of-allergy
European-academy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand .
Pharvaris N.V.February 26, 2021 GMT
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced dosing of the first patient in RAPIDe-1, an on-demand Phase 2 study evaluating the efficacy, safety, and pharmacokinetics of PHVS416 in patients with HAE due to C1-Inhibitor Deficiency type 1 and 2.
Chad
United-states
Switzerland
America
Berndt-modig
Maggie-beller
International-haei
Russo-partners
Inhibitor-deficiency
North-america
Solebury-trout
Business
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment .
Pharvaris N.V.February 19, 2021 GMT
ZUG, Switzerland, Feb. 19, 2021 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the presentation of clinical data supporting the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of PHA121 (PHA-022121) for the treatment of hereditary angioedema (HAE) at the 2021 American Academy of Allergy Asthma & Immunology (AAAAI) Virtual Annual Meeting, to be held Feb. 26 through March 1, 2021.
Chad
Switzerland
Peng-lu
Berndt-modig
Maggie-beller
American-academy-of-allergy-asthma-immunology
Russo-partners
Allergy-asthma
Virtual-annual-meeting
Solebury-trout
Business
Corporate-news
vimarsana © 2020. All Rights Reserved.